ReviewFrontiers in genetics2014
Epigenetic modulation in the treatment of atherosclerotic disease.
Review in Frontiers in genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Deep sequencing of circulating miRNAs and target mRNAs level in deep venous thrombosis patients.IET systems biology · 2023Article
- Chemically induced degradation of epigenetic targets.Chemical Society reviews · 2023Review
- Hypomethylation in MTNR1B: a novel epigenetic marker for atherosclerosis profiling using stenosis radiophenotype and blood inflammatory cells.Clinical epigenetics · 2023Article
- Sulforaphane alleviates hypoxic vestibular vertigo (HVV) by increasing NO production via upregulating the expression of NRF2.Bioengineered · 2022Article
- The link among microbiota, epigenetics, and disease development.Environmental science and pollution research international · 2021Review
- Promoter DNA Methylation in GWAS-Identified Genes as Potential Functional Elements for Blood Pressure: An Observational and Mendelian Randomization Study.Frontiers in genetics · 2021Article
- Phenethyl Isothiocyanate Protects against High Fat/Cholesterol Diet-Induced Obesity and Atherosclerosis in C57BL/6 Mice.Nutrients · 2020Article
- Integrative analysis identifies the association betweenNeurology. Genetics · 2020Article
- Promoter methylation changes in ALOX12 and AIRE1: novel epigenetic markers for atherosclerosis.Clinical epigenetics · 2020Article
- Early Programming of Adult Systemic Essential Hypertension.International journal of molecular sciences · 2020Review
- Article
- Prognostic significance of factor XIIIA promoter methylation status in aneurysmal subarachnoid haemorrhage (aSAH).BMC cardiovascular disorders · 2019Article
- Epigenomes in Cardiovascular Disease.Circulation research · 2018Review
- Chronic diseases, inflammation, and spices: how are they linked?Journal of translational medicine · 2018Review
- The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system.British journal of pharmacology · 2017Review
- TET2 Protects against oxLDL-Induced HUVEC Dysfunction by Upregulating the CSE/HFrontiers in pharmacology · 2017Article
- Epigenetic Mechanisms of the Aging Human Retina.Journal of experimental neuroscience · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is the single largest cause of death in the western world and its incidence is on the rise globally. Atherosclerosis, characterized by the development of atheromatus plaque, can trigger luminal narrowing and upon rupture result in myocardial infarction or ischemic stroke. Epigenetic phenomena are a focus of considerable research interest due to the role they play in gene regulation. Epigenetic mechanisms such as DNA methylation and histone acetylation have been identified as potential drug targets in the treatment of cardiovascular disease. miRNAs are known to play a role in gene silencing, which has been widely investigated in cancer. In comparison, the role they play in cardiovascular disease and plaque rupture is not well understood. Nutritional epigenetic modifiers from dietary components, for instance sulforaphane found in broccoli, have been shown to suppress the pro-inflammatory response through transcription factor activation. This review will discuss current and potential epigenetic therapeutics for the treatment of cardiovascular disease, focusing on the use of miRNAs and dietary supplements such as sulforaphane and protocatechuic aldehyde.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.